Vitamin D analog shuts down pancreatic cancer's shield in a clinical trial

A small clinical trial led by Dana-Farber Cancer Institute researchers has put a Salk Institute idea to the test in patients: that activating the vitamin D receptor can help reshape the protective environment surrounding pancreatic tumors in ways that could make the notoriously difficult-to-treat cancer more vulnerable to therapeutic treatments.